<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03546140</url>
  </required_header>
  <id_info>
    <org_study_id>Care_ChemS_ClinC -001-2017</org_study_id>
    <nct_id>NCT03546140</nct_id>
  </id_info>
  <brief_title>Diagnostic of Human Immunodeficiency Virus (HIV) and Other Sexual Transmission Diseases (STD) in High Risk Populations: Men Who Have Sex With Men (MSM) Users of Chemsex</brief_title>
  <acronym>Care_ChemS</acronym>
  <official_title>Diagnostic of Human Immunodeficiency Virus (HIV) and Other Sexual Transmission Diseases (STD) in High Risk Populations: Men Who Have Sex With Men (MSM) Users of Chemsex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to offer diagnostic tests for HIV, HCV and other STD in the risk group
      of men having sex with men (MSM) users of Chemsex
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to offer diagnostic tests for HIV, HCV and other STD in the risk group
      (MSM users of Chemsex) with the purpose of conduct diagnosis, early treatment and monitoring
      of this infections and reduce the incidence rate of the same ones
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of HIV,</measure>
    <time_frame>2 years</time_frame>
    <description>HIV positive serology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of HCV seroconversion</measure>
    <time_frame>2 years</time_frame>
    <description>HCV positive serology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number STD seroconversion</measure>
    <time_frame>2 years</time_frame>
    <description>positive serology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>type of consumer drug</measure>
    <time_frame>2 years</time_frame>
    <description>number and name ( Visual Analog Score for drug)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical outcomes</measure>
    <time_frame>2 years</time_frame>
    <description>number of hospital admissions for acute intoxications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analytical outcomes</measure>
    <time_frame>2 years</time_frame>
    <description>VDRL serology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analytical outcomes</measure>
    <time_frame>2 years</time_frame>
    <description>PCR CT/GN(pharynx / urethra / anus)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>2 years</time_frame>
    <description>in kilograms</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>HIV</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples and fixed tissues
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men MSM that come from HIV, urgency service and other from the hospital and from a local
        ONG
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (≥ 18 years)

          -  Men MSM/transgender referred from PEP office

          -  Men MSM/transgender referred from urgency service attended for acute intoxication or
             an STD

          -  Men MSM/transgender referred from STD office

          -  Men MSM/transgender referred from a local ONG attended for chemsex use

          -  Specifically drug use for having sexual relations, at least once in a month in the
             lasts 6 months or more than 10 times the last year

          -  Reading and understanding ability

          -  Patients should be given written informed consent

          -  Negative HIV and HCV men

          -  HIV positive men but HIC negative referred from HIV daily hospital

          -  Disposal of sanitary card from CatSalut

        Exclusion Criteria:

          -  Men that not accomplish inclusion criteria

          -  Drug use for another purposes not sexual

          -  Drug use for having occasional sexual relations, least than once in the past 6 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Cruceta, MD</last_name>
    <phone>932275400</phone>
    <phone_ext>4380</phone_ext>
    <email>acruceta@clinic.ub.es</email>
  </overall_contact>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 9, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Anna Cruceta</investigator_full_name>
    <investigator_title>Project manager Clinical Trials Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

